TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03312712

Intervention type: OTHER
Intervention: LPS Challenge
Description: In Part B, eight healthy volunteers will undergo an LPS challenge whereby each participant is injected with the challenge agent, Lipopolysaccharide (LPS), to invoke temporary mild lung inflammation. Each participant will have a PET/CT scan before and after the administration of LPS and the images will be assessed to determine whether these methods are able to detect true lung inflammation.

Intervention type: OTHER
Intervention: Saline Challenge
Description: In Part B, four healthy volunteers will undergo a saline challenge as outlined above for the LPS challenge. Pre- and post-challenge scans will provide control data for the study.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood and urine sampling
Description: For women whose post-menopausal status and/or pregnancy status is uncertain at screening, a blood sample will be collected to test for pregnancy and menopausal status (hormone profiling) before enrolling them on to the study. If pregnancy status is still uncertain at study visits, participants will have a urine pregnancy test before undergoing any PET/CT scans to ensure it is safe for them to continue in the study.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood and urine sampling
Description: For women whose post-menopausal status and/or pregnancy status is uncertain at screening, a blood sample will be collected to test for pregnancy and menopausal status (hormone profiling) before enrolling them on to the study. If pregnancy status is still uncertain at study visits, participants will have a urine pregnancy test before undergoing any PET/CT scans to ensure it is safe for them to continue in the study.
Study: NCT02196350

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention B: Exercise
Description: subjects visit the physiotherapist three times weekly; subjects visit the dietitian at week 0, 1, 2, 6, 10 and 13 for dietary advice.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention C: Diet and Exercise
Description: subjects visit the physiotherapist three times weekly; subjects visit the dietitian at week 0, 1, 2, 6, 10 and 13 for dietary advice.
Study: NCT04108650

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fit & Strong! group
Description: Consistent with the original format of F\&S!, the classes met three times per week for 90 minutes each for 8 weeks (24 sessions in total). Each class session consisted of 60 minutes of exercise and 30 minutes of health education. The exercise protocol included 10 minutes of warm-up and cool-down exercises, 20 minutes of low-intensity aerobic exercises, and 20 minutes of lower extremity strengthening exercises. The health education program focused on symptom management and behavioral strategies to increase physical activity and commitment to lifestyle change.
Study: NCT04278404

Intervention type: DRUG
Intervention: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
Description: The prescribing of drugs to children is not part of this protocol. Participants will receive DOIs as prescribed by their treating provider.
Study: NCT01784029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Doses are as mentioned above. Will repeat 3 month cycles of treatment if still deficient at 3 month follow up.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Doses are as mentioned above. Will repeat 3 month cycles of treatment if still deficient at 3 month follow up.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Doses are as mentioned above. Will repeat 3 month cycles of treatment if still deficient at 3 month follow up.
Study: NCT04551300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VS-505
Description: 4 dosages of experimental drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VS-505
Description: 4 dosages of experimental drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VS-505
Description: 4 dosages of experimental drug
Study: NCT04176588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrasimod
Description: Drug:Etrasimod Tablet other name:APD334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrasimod
Description: Drug:Etrasimod Tablet other name:APD334

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Drug:placebo Tablet
Study: NCT04551300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VS-505
Description: 4 dosages of experimental drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevelamer Carbonate
Description: Active Comparator
Study: NCT00822302

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reconstituted High Density Lipoprotein
Description: RecHDL (Lot Nos 05422-00006)is provided as a lyophilised powder and reconstituted with sterile water at 25 mg/ml. The infusion is made at 40 mg/kg over a period of 4 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline (0.9%) is provided as a sterile infusion bag and infused over a period of 4 hours, 24 hours prior to carotid endarterectomy
Study: NCT02840630

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tinned mackerel fish
Description: Diabetic fish intervention group will be given two tinned mackerels per week from week 0 until week 16.
Study: NCT02665910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR0302
Description: Oral tablets (1 mg, 5 mg, 10 mg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SHR0302 placebo comparator
Description: Oral tablets (1 mg, 5 mg, 10 mg) (matching corresponding study medication)
Study: NCT04129307

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor imagery
Description: This group will perform motor imagery training in combination with physical practice on motor learning of different motor tasks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Double time motor imagery
Description: This group will perform motor imagery training by doubling the intervention time to the motor imagery group in combination with physical practice on motor learning of various motor tasks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Action observation
Description: This group will perform action observation training in combination with physical practice on motor learning of various motor tasks.
Study: NCT01147302

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: C1 Esterase Inhibitor (Human)
Study: NCT01843530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berinert

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clemastin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Clemastin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cortisone acetate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cortisone acetate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl
Study: NCT01853709

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Study: NCT03926936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: intramuscular injection (2x 250mg), once every 2 weeks for the first month, and then monthly until completion of the study
Study: NCT05600647

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electromagnetic Field therapy with an exercise program
Description: 1. The magnetic field is generated through a mattress that is connected to the device. The maximum program, program 4, for 20 minutes with an intensity of 35 microtesla (level 10) and 50-60 Hz. the patient was lying on the mattress in a supine position.~2. the exercise program included postural correction strengthening exercises, stretching, proprioception and balance training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise program
Description: the exercise program included postural correction, strengthening exercises, stretching, proprioception and balance training
Study: NCT00145249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amphotericin B
Description: Amphotericin B 0.7 mg/kg IV for the first 14 days of treatment. This period may be extended up to an additional 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amphotericin B
Description: Amphotericin B 0.7 mg/kg IV for the first 14 days of treatment. This period may be extended up to an additional 7 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amphotericin B
Description: Amphotericin B 0.7 mg/kg IV for the first 14 days of treatment. This period may be extended up to an additional 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole
Description: Fluconazole 400 or 800 mg daily. Among subjects whose baseline weight is less than 40 kg, randomized fluconazole doses will be 200 mg/kg daily or 400 mg/kg daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole
Description: Fluconazole 400 or 800 mg daily. Among subjects whose baseline weight is less than 40 kg, randomized fluconazole doses will be 200 mg/kg daily or 400 mg/kg daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluconazole
Description: Fluconazole 400 or 800 mg daily. Among subjects whose baseline weight is less than 40 kg, randomized fluconazole doses will be 200 mg/kg daily or 400 mg/kg daily.
Study: NCT04653142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 765063
Description: BI 765063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 754091
Description: BI 754091
Study: NCT03529383

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Connected device
Description: Women will receive a connected wristband (https://www.carefitness.com/) and a subscription to a smartphone application and website (http://disco.biomouv.com/). They will have to participate in a 6-month personalized non-supervised exercise program consisting of 3 weekly sessions of 20 min to 1-hr of moderate-to-vigorous physical activity (≥3 METs): 2 sessions of brisk walking and 1 session of muscle strengthening. Women should wear the wristband daily to track their number of steps (automatic Bluetooth synchronization to the application). Duration and intensity of sessions and target number of daily steps will progressively increase (+15% up to 10,000 steps) to place the patients in a progression dynamic. Women will receive phone-based follow-up at 1 week, 2 months, and 4 months.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Connected device
Description: Women will receive a connected wristband (https://www.carefitness.com/) and a subscription to a smartphone application and website (http://disco.biomouv.com/). They will have to participate in a 6-month personalized non-supervised exercise program consisting of 3 weekly sessions of 20 min to 1-hr of moderate-to-vigorous physical activity (≥3 METs): 2 sessions of brisk walking and 1 session of muscle strengthening. Women should wear the wristband daily to track their number of steps (automatic Bluetooth synchronization to the application). Duration and intensity of sessions and target number of daily steps will progressively increase (+15% up to 10,000 steps) to place the patients in a progression dynamic. Women will receive phone-based follow-up at 1 week, 2 months, and 4 months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic education
Description: Women will be invited to participate in the 6-month therapeutic patient education program Mieux manger, mieux bouger (Eat better, move better) elaborated at the Léon Bérard cancer center. The program consists in four sessions:~* a 1-hour individual session of educational diagnosis to assess their needs and establish a contract of objectives,~* two educational sessions of 1h30 each using tools, in group of 10 patients maximum to improve their daily practice of physical activity,~* a 1-hour individual session of educational assessment to evaluate whether their objectives were reached.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic education
Description: Women will be invited to participate in the 6-month therapeutic patient education program Mieux manger, mieux bouger (Eat better, move better) elaborated at the Léon Bérard cancer center. The program consists in four sessions:~* a 1-hour individual session of educational diagnosis to assess their needs and establish a contract of objectives,~* two educational sessions of 1h30 each using tools, in group of 10 patients maximum to improve their daily practice of physical activity,~* a 1-hour individual session of educational assessment to evaluate whether their objectives were reached.
Study: NCT04305886

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Discussion Guide
Description: Written list of prompts to facilitate discussion
Study: NCT03926936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: intramuscular injection (2x 250mg), once every 2 weeks for the first month, and then monthly until completion of the study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: intramuscular injection (2x 250mg), once every 2 weeks for the first month, and then monthly until completion of the study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: intramuscular injection (2x 250mg), once every 2 weeks for the first month, and then monthly until completion of the study
Study: NCT03667911

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: virtual reality videos
Description: Watch virtual reality videos after routine patient education(both oral and written instructions). Videos give instructions on correct steps of bowel preparation, points for attention, as well as actual images of bowel during colonoscopy in the case of both excellent and unsatisfactory bowel preparation.
Study: NCT01305252

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: treprostinil inhalations
Description: Treprostinil inhalation QID starting at 3 breaths per inhalation \& gradually increasing to 9 breaths. Each breath provides approximately 6mcg of treprostinil.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tadalafil
Description: tadalafil 20mg QD PO increasing to 40mg QD as tolerated

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tadalafil
Description: tadalafil 20mg QD PO increasing to 40mg QD as tolerated
Study: NCT02259543

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Root conditioning with citric acid+tetracycline solution
Description: Application of a citric acid + tetracycline gel solution (1:1) for decontamination of root surfaces during the treatment of recession defects by subepithelial connective tissue graft

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Root conditioning with citric acid+tetracycline solution
Description: Application of a citric acid + tetracycline gel solution (1:1) for decontamination of root surfaces during the treatment of recession defects by subepithelial connective tissue graft
Study: NCT01116635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin, superabsorbent polymer microspheres, embolotherapy
Description: varying doses of doxorubicin loaded onto SAP during embolization procedure. Pharmacokinetic analysis of elution profile through serum concentrations over 1 month period embolization of surgically resectable HCC with superabsorbent polymer microspheres loaded with doxorubicin from a single treatment. Phase I will follow a modified Fibonacci sequence (with pharmacokinetic analysis of serum doxorubicin) to determine mean tolerated dose (MTD), severe adverse reaction (SAE) and dose limiting toxicities (DLT) when microspheres are loaded with 25mg, 50mg, or 75mg of doxorubicin. Phase II will continue enrollment with the two highest tolerated doses. At least one month after treatment, all patients will undergo imaging and surgical resection of reference tumor, with assessment of degree of necrosis, microsphere distribution, and correlation with concentration of doxorubicin loaded onto microsphere.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin, superabsorbent polymer microspheres, embolotherapy
Description: varying doses of doxorubicin loaded onto SAP during embolization procedure. Pharmacokinetic analysis of elution profile through serum concentrations over 1 month period embolization of surgically resectable HCC with superabsorbent polymer microspheres loaded with doxorubicin from a single treatment. Phase I will follow a modified Fibonacci sequence (with pharmacokinetic analysis of serum doxorubicin) to determine mean tolerated dose (MTD), severe adverse reaction (SAE) and dose limiting toxicities (DLT) when microspheres are loaded with 25mg, 50mg, or 75mg of doxorubicin. Phase II will continue enrollment with the two highest tolerated doses. At least one month after treatment, all patients will undergo imaging and surgical resection of reference tumor, with assessment of degree of necrosis, microsphere distribution, and correlation with concentration of doxorubicin loaded onto microsphere.
Study: NCT03625622

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AR1001
Description: AR1001 Active Oral Tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AR1001
Description: AR1001 Active Oral Tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Oral Tablet
Study: NCT03032913

Intervention type: PROCEDURE
Intervention: Blood samples
Description: Blood samples for both group

Intervention type: PROCEDURE
Intervention: Blood samples
Description: Blood samples for both group

Intervention type: PROCEDURE
Intervention: Portal vein blood sample
Description: Portal vein blood sample during surgery procedure for the Pancreatic Ductal Adenocarcinoma group
Study: NCT01714960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRZ-99030 eye drops 5mg/mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRZ-99030 eye drops 20mg/mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRZ-99030 eye drops 20mg/mL

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to MRZ-99030 eye drops
Study: NCT03409913

Intervention type: RADIATION
Intervention: FDG PET/CT
Description: Conventional FDG PET/CT including head in order to asses cranial arteries.

Intervention type: RADIATION
Intervention: FDG PET/CT
Description: Conventional FDG PET/CT including head in order to asses cranial arteries.
Study: NCT03311893

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: natural orifice surgery
Description: evaluation of the awareness of the use of transvaginal, transoral and transcranial approach in surgical excision and the difference between the health staff and the pathology
Study: NCT03509714

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Jubilance (100 mg Oxaloacetate/150 mg Ascorbic Acid)
Description: 2 Pills to be taken orally per day during their entire menstrual cycle

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Jubilance (100 mg Oxaloacetate/150 mg Ascorbic Acid)
Description: 2 Pills to be taken orally per day during their entire menstrual cycle

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: rice flour (Placebo)
Description: 250 mg rice flour (Placebo)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: rice flour (Placebo)
Description: 250 mg rice flour (Placebo)
Study: NCT04126616

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: chest Magnetic Resonance Imaging (MRI) using Gadolinium-based contrast agent
Description: chest MRI will be performed at rest and after moderate exercise

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: chest Magnetic Resonance Imaging (MRI) using Gadolinium-based contrast agent
Description: chest MRI will be performed at rest and after moderate exercise

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: chest Magnetic Resonance Imaging (MRI) using Gadolinium-based contrast agent
Description: chest MRI will be performed at rest and after moderate exercise
Study: NCT01583517

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biliary sphincterotomy
Description: Cutting of the biliary sphincter muscle.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biliary sphincterotomy
Description: Cutting of the biliary sphincter muscle.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pancreatobiliary sphincterotomy
Description: Cutting of both the biliary and pancreatic sphincter muscles.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: No sphincterotomy is performed in patients randomized to sham with normal SOM.
Study: NCT03507413

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin Glucophage 500mg (IR) tablets M90
Description: oral metformin Glucophage treatment 500 mg daily (2-0-2) for 1 year

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo Oral Tablet M90 treatment twice daily (2-0-2) for 1 year
Study: NCT03176368

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coconut Oil
Description: Coconut Oil
Study: NCT01393457

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levodopa/carbidopa
Description: 800/200 mg/d

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levodopa/carbidopa
Description: 800/200 mg/d

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levodopa/carbidopa
Description: 800/200 mg/d

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropinirole 2 mg/d
Description: 2 mg/d

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: sugar pill

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropinirole 4 mg/d
Description: 4 mg/d
Study: NCT04704349

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Scintigraphy
Description: The scintigraphy of the patients will be carried out on 2 distinct devices and the images obtained will be compared.